{
    "clinical_study": {
        "@rank": "70369", 
        "arm_group": {
            "arm_group_label": "Cohort Group", 
            "description": "Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician."
        }, 
        "brief_summary": {
            "textblock": "This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra\u2122) used in\n      routine practice in children aged 12 months to 12 years living in the Philippines."
        }, 
        "brief_title": "Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra\u2122 in Children Living in the Philippines", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Mumps", 
            "Rubella", 
            "Measles", 
            "Varicella"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Chickenpox", 
                "Herpes Zoster", 
                "Measles", 
                "Mumps", 
                "Parotitis", 
                "Rubella"
            ]
        }, 
        "detailed_description": {
            "textblock": "The participating physicians will enroll only those subjects for whom they would prescribe\n      Priorix-Tetra in the course of their normal clinical practice."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who the investigator believes that parent(s)/Legally Acceptable\n             Representative(s) [LAR(s)] can and will comply with the requirements of the protocol.\n\n          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject.\n\n          -  Male or female subjects living in the Philippines between, and including, the ages of\n             12 months and 12 years at the time of the vaccination.\n\n          -  Female subjects of child bearing potential may be enrolled in the study, if the\n             subject:\n\n               -  has agreed to be abstinent or practiced adequate contraception for 30 days prior\n                  to vaccination, and\n\n               -  has a negative pregnancy test on the day of vaccination, and\n\n               -  has agreed to continue adequate contraception during the entire treatment period\n                  and for 3 months after completion of the vaccination.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Any contraindications to vaccination as stated in the Prescribing Information.\n\n          -  Acute, severe febrile illness at the time of enrollment. The presence of a minor\n             infection, such as a cold, will not exclude the subject from the study.\n\n          -  Previous receipt of a measles, mumps, rubella and/or varicella-virus containing\n             vaccine less than 3 months prior to study entry.\n\n          -  Previous enrolment in this trial.\n\n          -  Subjects with impaired immune function, including primary or secondary\n             immunodeficiencies based on medical history.\n\n          -  History of hypersensitivity to any component of the vaccine.\n\n          -  History of hypersensitivity following previous administration of measles, mumps,\n             rubella and/or varicella-virus containing vaccines.\n\n          -  Receipt of human gamma globulins or a blood transfusion within 3 months prior to\n             study entry.\n\n          -  Hypersensitivity to latex.\n\n          -  Pregnant or lactating female."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "12 Months", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Children aged 12 months to 12 years living in Philippines will receive Priorix-Tetra as\n        prescribed by the physician."
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738841", 
            "org_study_id": "114229"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort Group", 
                "description": "Single dose, subcutaneous injection", 
                "intervention_name": "Priorix-Tetra\u2122", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Cohort Group", 
                "description": "Recording of adverse events, using diary cards", 
                "intervention_name": "Safety data collection", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetracycline"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Combined measles-mumps-rubella-varicella vaccine", 
            "Priorix-Tetra\u2122", 
            "MMRV", 
            "children", 
            "Post-marketing surveillance", 
            "Philippines"
        ], 
        "lastchanged_date": "July 18, 2013", 
        "number_of_groups": "1", 
        "official_title": "Post-marketing Surveillance Study of GSK Biologicals' Live, Attenuated Measles, Mumps, Rubella and Varicella Vaccine, Priorix-Tetra, Following a Single Vaccine Dose Given According to Local Prescribing Information in the Philippines", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Philippines: Food and Drug Administration Philippines"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of Grade 3 adverse events (AEs) with a causal relationship to vaccination", 
            "safety_issue": "No", 
            "time_frame": "Between Day 0 and Day 42"
        }, 
        "removed_countries": {
            "country": "Philippines"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738841"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of Grade 3 AEs", 
                "safety_issue": "No", 
                "time_frame": "Between Day 0 and Day 42"
            }, 
            {
                "measure": "Occurrence of medically-attended AEs", 
                "safety_issue": "No", 
                "time_frame": "Between Day 0 and Day 42"
            }, 
            {
                "measure": "Occurrence of Serious Adverse Events (SAEs)", 
                "safety_issue": "No", 
                "time_frame": "From the time of vaccination (Week 0) to study end (Week 6)"
            }, 
            {
                "measure": "Occurrence of febrile convulsions", 
                "safety_issue": "No", 
                "time_frame": "Between Day 0 and Day 42"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013", 
        "why_stopped": "Local authorities no longer require routine PMS studies; GSK does not believe the study would\n    add meaningfully to the safety data already available for MMRV."
    }
}